Shire’s Vyvanse logged $145M in 4Q09 sales and almost $505M annualy. Intuniv sales were $5.4M since launch in November 2009 but Shire said deferred revenues on the balance sheet represented gross sales of $38.8M.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.